Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Lung immune incompetency after mild peritoneal sepsis and its partial restoration by type 1 interferon: a mouse model study.
Intensive Care Med Exp
December 2024
Department of Anesthesiology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-0033, Japan.
Background: Sepsis is commonly associated with acute respiratory distress syndrome (ARDS). Although the exaggerated inflammation may damage intact lung tissues, a percentage of patients with ARDS are reportedly immunocompromised, with worse outcomes. Herein, using a murine sepsis model, time-course immune reprogramming after sepsis was evaluated to explore whether the host is immunocompromised.
View Article and Find Full Text PDFCharacteristics of long-survivor metastatic melanoma after polychemotherapy and interferon: a retrospective study.
Swiss Med Wkly
December 2023
Department of Oncology, Hôpitaux Universitaires de Genève, Geneva, Switzerland.
Background: The development of immunotherapy and tyrosine kinase inhibitors dramatically improved the prognosis of metastatic melanoma. Consequently, chemotherapy is now rarely used. Here, we describe the characteristics of long-surviving patients with metastatic melanoma treated with immunochemotherapy.
View Article and Find Full Text PDFCombining PD-1/PD-L1 blockade with type I interferon in cancer therapy.
Front Immunol
September 2023
Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
PD-1 and PD-L1 are crucial regulators of immunity expressed on the surface of T cells and tumour cells, respectively. Cancer cells frequently use PD-1/PD-L1 to evade immune detection; hence, blocking them exposes tumours to be attacked by activated T cells. The synergy of PD-1/PD-L1 blockade with type I interferon (IFN) can improve cancer treatment efficacy.
View Article and Find Full Text PDFImidazoquinolines with improved pharmacokinetic properties induce a high IFNα to TNFα ratio and .
Front Immunol
July 2023
Synovo GmbH, Tübingen, Germany.
TLR Agonists have promising activity in preclinical models of viral infection and cancer. However, clinical use is only in topical application. Systemic uses of TLR-ligands such as Resiquimod, have failed due to adverse effects that limited dose and thus, efficacy.
View Article and Find Full Text PDFSingle-cell RNA sequencing reveals the role of cell heterogeneity in the sex difference in primary hyperparathyroidism.
Front Endocrinol (Lausanne)
March 2023
Department of Orthopedic Trauma, Beijing Jishuitan Hospital, Beijing, China.
Objective: To explore the difference in parathyroid tissue-derived cells between male and female PHPT patients.
Methods: Resected parathyroid tissues were collected from PHPT patients of both sexes. Single cells were isolated and sequenced for RNA expression profiles.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!